查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2148906

脊髓性肌肉萎縮症治療市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測

Spinal Muscular Atrophy Treatment Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

脊髓性肌肉萎縮症治療市場的成長要素

2025年全球脊髓性肌肉萎縮症（SMR）治療市場規模為52.5億美元，預計2026年將達62.6億美元，到2034年將成長至257.2億美元。該市場預計在2026年至2034年間將以19.31%的複合年成長率成長。北美在全球市場中佔據領先地位，2025年市場佔有率達到49.65%，這得益於先進療法的早期獲批、有利的保險報銷政策以及患者治療率的提高。

脊髓性肌肉萎縮症 (SMA) 是一種罕見的遺傳性神經肌肉疾病，可導致進行性性肌肉無力和嚴重殘疾，尤其在患有 1 型 SMA 的嬰兒中更為嚴重。 SMA 盛行率的上升、公眾意識的提高、診斷技術的進步以及疾病修正治療的日益普及，正在推動市場成長。諸如 Spinraza 和 Zolgensma 等高附加價值療法正在改變治療方法，並提升全球 SMA 治療市場的價值。

市場趨勢

脊髓性肌肉萎縮症 (SMA) 治療市場的一個關鍵趨勢是，對創新療法的研發投入不斷增加。製藥公司正在開發一系列候選藥物，旨在提高治療效果、可及性和患者預後。基因療法和其他先進治療方法的出現，正在為整個 SMA 治療行業創造新的機會。

另一個重要趨勢是保險覆蓋範圍的擴大。在一些國家，昂貴的脊髓性肌肉萎縮症（SMA）治療費用已納入保險範圍，使患者更容易獲得先進的治療。預計保險覆蓋範圍的擴大將促進治療的普及，尤其是在醫療市場成熟的國家。

市場促進因素

SMA盛行率和大眾意識不斷提高：

脊髓性肌肉萎縮症（SMA）確診病例的不斷增加，推動了對有效治療方法的需求。醫護人員和病患家屬對SMA嚴重性的認知不斷提高，有助於早期診斷和治療。

先進高效療法的出現：

Spinraza（nusinersen）和Zolgensma（onasemnogen/aveparvovec）的上市顯著改變了脊髓性肌肉萎縮症（SMA）的治療格局。這些藥物能夠針對疾病的潛在機制並改善患者預後，從而支撐了市場現狀。

市場限制與挑戰

高昂的醫療費用：

已通過核准的脊髓性肌肉萎縮症（SMA）治療藥物價格極為昂貴，仍是主要限制因素。 Spinraza 可能導致持續的巨額治療費用，而 Zulgensma 先前定價為一次性治療，費用約為 210 萬美元。這些高昂的費用可能會限制醫療預算有限或保險覆蓋不足的國家獲得治療的機會。

其他挑戰包括監管複雜性、發展中地區意識水平低、診斷延遲以及需要專門的治療基礎設施。

細分分析

副產品：

在市場區隔方面，nusinersen 和 onasemnogene abeparbovec 各具特色。由於 Nusinersen 較早獲得市場批准並被廣泛應用，因此歷史上佔據了最大的市場佔有率。隨著基因療法在更多市場的應用，onasemnogene abeparbovec 預計將獲得成長動力。

依疾病類型：

市場涵蓋第1型脊髓性肌肉萎縮症（SMA）、第2型SMA及其他類型。由於第1型SMA病情嚴重且治療需求高，因此在市場中佔據主導地位。

按分銷管道：

分銷管道包括醫院藥房、零售藥房等。由於脊髓性肌肉萎縮症（SMA）的治療需要由訓練有素的醫護人員進行給藥和監測，因此醫院藥房歷來佔據主導地位。

區域分析

北美是一個重要的區域市場，預計到 2025 年將佔全球市場的 49.65%。該地區受益於較早的監管批准、先進的醫療保健基礎設施、有利的保險報銷政策和不斷提高的治療率。

在保險覆蓋範圍擴大和醫療保健體系健全的支持下，歐洲預計將繼續保持第二大區域市場的地位。

由於各國政府和私營機構加大了對罕見疾病治療的投入，亞太地區預計將迎來顯著成長。雖然日本已為脊髓性肌肉萎縮症（SMA）治療提供保險保障，但隨著其他亞洲市場治療可近性的提高，預計未來將有更多發展機會。

雖然拉丁美洲疾病意識的提高是一個利好因素，但由於一些國家診斷延遲和醫療基礎設施不足，預計中東和非洲市場將經歷緩慢至中等的成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇

第4章：主要考慮因素

  • 主要國家脊髓性肌肉萎縮症的盛行率
  • 主要行業趨勢
  • 管道分析
  • 新產品發布
  • 兌換狀態：依主要國家分類
  • 監理展望
  • 主要行業趨勢

第5章：2021-2034年全球脊髓性肌肉萎縮症治療市場分析、洞察與預測

  • 主要發現與總結
  • 市場分析、洞察與預測：按產品類型分類
    • 努西納森
    • 奧納塞姆諾根·阿貝帕博貝克
  • 市場分析、洞察與預測：按疾病類型分類
    • 1 型 SMA
    • 2 型 SMA
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第6章：北美脊髓性肌肉萎縮症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲脊髓性肌肉萎縮症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲國家

第8章：亞太地區脊髓性肌肉萎縮症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 其他亞太國家

第9章：2021-2034年其他地區脊髓性肌肉萎縮症治療的全球市場分析、洞察與預測

第10章 競爭分析

  • 主要行業趨勢
  • 全球市佔率分析（2025 年）
  • 競爭對手儀錶板
  • 主要公司比較分析
  • 公司簡介
    • Biogen
    • Novartis AG
    • Genentech, Inc./F. Hoffmann-La Roche Ltd
    • Astellas Pharma Inc.
    • Genzyme Corporation
    • Other Prominent Players
Product Code: FBI100576

Growth Factors of spinal muscular atrophy treatment Market

The global spinal muscular atrophy treatment market size was valued at USD 5.25 billion in 2025 and is projected to reach USD 6.26 billion in 2026, expanding to USD 25.72 billion by 2034. The market is expected to register a CAGR of 19.31% during 2026-2034. North America dominated the global market with a 49.65% market share in 2025, supported by early approvals of advanced therapies, favorable reimbursement policies, and increasing patient treatment rates.

Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disorder that can cause progressive muscle weakness and severe disability, particularly in infants with Type 1 SMA. The increasing incidence of SMA, growing awareness, improved diagnosis, and the availability of disease-modifying therapies are strengthening market growth. High-value treatments such as Spinraza and Zolgensma have significantly transformed the treatment landscape and increased the value of the global SMA treatment market.

Market Trends

A major spinal muscular atrophy treatment market trend is the increasing investment in research and development for innovative therapies. Pharmaceutical companies are developing pipeline candidates designed to improve treatment efficacy, accessibility, and patient outcomes. The emergence of gene therapy and other advanced therapeutic approaches is creating new opportunities across the SMA treatment industry.

Another important trend is the expansion of reimbursement access. Several countries have introduced reimbursement programs for expensive SMA therapies, improving patient access to advanced treatments. Greater reimbursement coverage is expected to support treatment adoption, particularly in developed healthcare markets.

Market Drivers

Growing Incidence and Awareness of SMA:

The increasing diagnosis of spinal muscular atrophy is supporting demand for effective therapies. Rising awareness among healthcare professionals and families regarding the severity of SMA is encouraging earlier diagnosis and treatment.

Launch of Advanced and Highly Effective Therapies:

The introduction of Spinraza (Nusinersen) and Zolgensma (Onasemnogene abeparvovec) has substantially changed the SMA treatment landscape. Their ability to address the underlying disease mechanism and improve patient outcomes is supporting market growth.

Market Restraints and Challenges

High Treatment Costs:

The extremely high cost of approved SMA therapies remains a significant restraint. Spinraza can involve substantial recurring treatment costs, while Zolgensma has historically carried a one-time treatment price of approximately USD 2.1 million. These costs can limit accessibility in countries with restricted healthcare budgets or inadequate reimbursement coverage.

Other challenges include regulatory complexity, limited awareness in developing regions, delayed diagnosis, and the need for specialized treatment infrastructure.

Segmentation Analysis

By Product:

The market is segmented into Nusinersen and Onasemnogene Abeparvovec. Nusinersen held the largest historical share due to its earlier market approval and widespread adoption. Onasemnogene Abeparvovec is expected to gain momentum as gene therapy adoption expands across additional markets.

By Disease Type:

The market includes Type 1 SMA, Type 2 SMA, and Others. Type 1 SMA held the dominant position because of the severity and high treatment requirements associated with this form of the disease.

By Distribution Channel:

Distribution channels include hospital pharmacies, retail pharmacies, and others. Hospital pharmacies have historically maintained the leading position because SMA therapies require administration and monitoring by trained healthcare professionals.

Regional Analysis

North America represented the leading regional market, accounting for 49.65% of the global market in 2025. The region benefits from early regulatory approvals, advanced healthcare infrastructure, favorable reimbursement policies, and increasing treatment rates.

Europe is expected to remain the second-largest regional market, supported by increasing reimbursement access and strong healthcare systems.

Asia Pacific is projected to experience significant growth as governments and private organizations increase funding for rare-disease treatments. Japan has supported reimbursed access to SMA therapies, while improving treatment accessibility in other Asian markets is expected to create further opportunities.

Latin America is benefiting from increasing disease awareness, while the Middle East & Africa market is expected to experience slower-to-moderate growth because of delayed diagnosis and limited healthcare infrastructure in several countries.

Key Industry Players

Major companies operating in the SMA treatment market include Biogen, Novartis AG, Genentech/F. Hoffmann-La Roche Ltd, Astellas Pharma Inc., and Genzyme Corporation. Biogen and Novartis have maintained strong competitive positions through Spinraza and Zolgensma, while other pharmaceutical companies continue developing pipeline therapies.

Recent Industry Developments

In May 2019, Novartis' Zolgensma received U.S. FDA approval as a gene therapy for pediatric patients with SMA. In December 2016, the U.S. FDA approved Biogen's Spinraza as the first drug specifically approved for the treatment of spinal muscular atrophy.

Future Outlook

The spinal muscular atrophy treatment market outlook remains strong due to increasing diagnosis, continued clinical research, product launches, expanding reimbursement programs, and growing adoption of gene therapies. The market is expected to expand from USD 5.25 billion in 2025 to USD 6.26 billion in 2026 and USD 25.72 billion by 2034. Increasing investment in rare-disease research and the development of more accessible treatment options will remain important factors shaping the market.

Conclusion

The global spinal muscular atrophy treatment market is entering a strong growth phase, supported by advanced therapies, increasing disease awareness, improved diagnosis, and expanding reimbursement coverage. North America currently represents the leading market, while Asia Pacific offers significant future opportunities as treatment accessibility improves. Although high therapy costs remain a major challenge, continued innovation in gene therapy, pipeline development, and supportive healthcare policies are expected to drive substantial market expansion through 2034.

Unit Value (USD million)

Segmentation By Product

  • Nusinersen
  • Onasemnogen Abeparvovec

By Disease Type

  • Type 1 SMA
  • Type 2 SMA
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, and Rest of Asia Pacific)
  • Rest of the World

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Spinal Muscular Atrophy for Key Countries
  • 4.2. Key Industry Developments
  • 4.3. Pipeline Analysis
  • 4.4. New Product Launches
  • 4.5. Reimbursement Scenario by Key Countries
  • 4.6. Regulatory Scenario
  • 4.7. Key Industry Trends

5. Global Spinal Muscular Atrophy (SMA) Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Product Type
    • 5.2.1. Nusinersen
    • 5.2.2. Onasemnogen Abeparvovec
  • 5.3. Market Analysis, Insights and Forecast - By Disease Type
    • 5.3.1. Type 1 SMA
    • 5.3.2. Type 2 SMA
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of the World

6. North America Spinal Muscular Atrophy (SMA) Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Product Type
    • 6.2.1. Nusinersen
    • 6.2.2. Onasemnogen Abeparvovec
  • 6.3. Market Analysis - By Disease Type
    • 6.3.1. Type 1 SMA
    • 6.3.2. Type 2 SMA
    • 6.3.3. Others
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Others
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Spinal Muscular Atrophy (SMA) Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Product Type
    • 7.2.1. Nusinersen
    • 7.2.2. Onasemnogen Abeparvovec
  • 7.3. Market Analysis - By Disease Type
    • 7.3.1. Type 1 SMA
    • 7.3.2. Type 2 SMA
    • 7.3.3. Others
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Others
  • 7.5. Market Analysis - By Country/ sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Rest of Europe

8. Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Product Type
    • 8.2.1. Nusinersen
    • 8.2.2. Onasemnogen Abeparvovec
  • 8.3. Market Analysis - By Disease Type
    • 8.3.1. Type 1 SMA
    • 8.3.2. Type 2 SMA
    • 8.3.3. Others
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Others
  • 8.5. Market Analysis - By Country/ sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Rest of Asia Pacific

9. Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Product Type
    • 9.2.1. Nusinersen
    • 9.2.2. Onasemnogen Abeparvovec
  • 9.3. Market Analysis - By Disease Type
    • 9.3.1. Type 1 SMA
    • 9.3.2. Type 2 SMA
    • 9.3.3. Others
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Others

10. Competitive Analysis

  • 10.1. Key Industry Developments
  • 10.2. Global Market Share Analysis (2025)
  • 10.3. Competition Dashboard
  • 10.4. Comparative Analysis - Major Players
  • 10.5. Company Profiles
    • 10.5.1. Biogen
      • 10.5.1.1. Overview,
      • 10.5.1.2. Products & services,
      • 10.5.1.3. SWOT analysis,
      • 10.5.1.4. Recent developments,
      • 10.5.1.5. strategies,
      • 10.5.1.6. financials (based on availability)
    • 10.5.2. Novartis AG
      • 10.5.2.1. Overview,
      • 10.5.2.2. Products & services,
      • 10.5.2.3. SWOT analysis,
      • 10.5.2.4. Recent developments,
      • 10.5.2.5. strategies,
      • 10.5.2.6. financials (based on availability)
    • 10.5.3. Genentech, Inc./ F. Hoffmann-La Roche Ltd
      • 10.5.3.1. Overview,
      • 10.5.3.2. Products & services,
      • 10.5.3.3. SWOT analysis,
      • 10.5.3.4. Recent developments,
      • 10.5.3.5. strategies,
      • 10.5.3.6. financials (based on availability)
    • 10.5.4. Astellas Pharma Inc.
      • 10.5.4.1. Overview,
      • 10.5.4.2. Products & services,
      • 10.5.4.3. SWOT analysis,
      • 10.5.4.4. Recent developments,
      • 10.5.4.5. strategies,
      • 10.5.4.6. financials (based on availability)
    • 10.5.5. Genzyme Corporation
      • 10.5.5.1. Overview,
      • 10.5.5.2. Products & services,
      • 10.5.5.3. SWOT analysis,
      • 10.5.5.4. Recent developments,
      • 10.5.5.5. strategies,
      • 10.5.5.6. financials (based on availability)
    • 10.5.6. Other Prominent Players
      • 10.5.6.1. Overview,
      • 10.5.6.2. Products & services,
      • 10.5.6.3. SWOT analysis,
      • 10.5.6.4. Recent developments,
      • 10.5.6.5. strategies,
      • 10.5.6.6. financials (based on availability)

List of Tables

  • Table 1: Global Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
  • Table 2: Global Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 3: Global Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Region, 2025-2034
  • Table 5: North America Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Product, 2025-2034
  • Table 6: North America Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2025-2034
  • Table 7: North America Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2025-2034
  • Table 8: North America Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, By Country, 2025-2034
  • Table 9: Europe Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Product, 2025-2034
  • Table 10: Europe Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2025-2034
  • Table 11: Europe Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2025-2034
  • Table 12: Europe Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2025-2034
  • Table 13: Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Product, 2025-2034
  • Table 14: Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2025-2034
  • Table 15: Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2025-2034
  • Table 16: Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2025-2034
  • Table 17: Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Product, 2025-2034
  • Table 18: Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2025-2034
  • Table 19: Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2025-2034
  • Table 20: Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2025-2034

List of Figures

  • Figure 1: Global Spinal Muscular Atrophy (SMA) Treatment Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Spinal Muscular Atrophy (SMA) Treatment Market Forecast (US$ Mn), by Nusinersen, 2025-2034
  • Figure 4: Global Spinal Muscular Atrophy (SMA) Treatment Market Forecast (US$ Mn), by Onasemnogen Abeparvovec, 2025-2034
  • Figure 5: Global Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Disease Type, 2025 & 2034
  • Figure 6: Global Spinal Muscular Atrophy (SMA) Treatment Market Forecast (US$ Mn), by Type 1 SMA, 2025-2034
  • Figure 7: Global Spinal Muscular Atrophy (SMA) Treatment Market Forecast (US$ Mn), by Type 2 SMA, 2025-2034
  • Figure 8: Global Spinal Muscular Atrophy (SMA) Treatment Market Forecast (US$ Mn), by Others, 2025-2034
  • Figure 9: Global Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 10: Global Spinal Muscular Atrophy (SMA) Treatment Market Forecast (US$ Mn), by Hospital Pharmacies, 2025-2034
  • Figure 11: Global Spinal Muscular Atrophy (SMA) Treatment Market Forecast (US$ Mn), by Retail Pharmacies, 2025-2034
  • Figure 12: Global Spinal Muscular Atrophy (SMA) Treatment Market Forecast (US$ Mn), by Others, 2025-2034
  • Figure 13: Global Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 14: North America Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Product, 2025 & 2034
  • Figure 15: North America Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Product, 2025
  • Figure 16: North America Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 17: North America Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 18: North America Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 19: North America Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: North America Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 21: North America Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), By Country, 2025
  • Figure 22: Europe Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Product, 2025 & 2034
  • Figure 23: Europe Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Product, 2025
  • Figure 24: Europe Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 25: Europe Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 26: Europe Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 27: Europe Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Europe Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Europe Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Product, 2025 & 2034
  • Figure 31: Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Product, 2025
  • Figure 32: Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 33: Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 34: Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 35: Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Product, 2025 & 2034
  • Figure 39: Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Product, 2025
  • Figure 40: Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 41: Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 42: Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 43: Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Spinal Muscular Atrophy (SMA) Treatment Market Share (%), By Company, 2025